- Home
- SD vs KMDA Comparison
SD vs KMDA Comparison
Compare SD & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- KMDA
- Stock Information
- Founded
- SD 2006
- KMDA 1990
- Country
- SD United States
- KMDA Israel
- Employees
- SD N/A
- KMDA N/A
- Industry
- SD Oil & Gas Production
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- KMDA Health Care
- Exchange
- SD Nasdaq
- KMDA Nasdaq
- Market Cap
- SD 380.8M
- KMDA 399.7M
- IPO Year
- SD 2007
- KMDA N/A
- Fundamental
- Price
- SD $11.93
- KMDA $7.20
- Analyst Decision
- SD
- KMDA Strong Buy
- Analyst Count
- SD 0
- KMDA 3
- Target Price
- SD N/A
- KMDA $14.67
- AVG Volume (30 Days)
- SD 402.6K
- KMDA 71.8K
- Earning Date
- SD 08-06-2025
- KMDA 08-13-2025
- Dividend Yield
- SD 3.69%
- KMDA 2.77%
- EPS Growth
- SD 33.83
- KMDA 31.21
- EPS
- SD 1.74
- KMDA 0.28
- Revenue
- SD $137,611,000.00
- KMDA $167,235,000.00
- Revenue This Year
- SD $37.50
- KMDA $14.51
- Revenue Next Year
- SD $5.17
- KMDA $9.31
- P/E Ratio
- SD $6.84
- KMDA $26.07
- Revenue Growth
- SD 1.35
- KMDA 11.83
- 52 Week Low
- SD $8.81
- KMDA $4.74
- 52 Week High
- SD $14.04
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- SD 76.46
- KMDA 65.83
- Support Level
- SD $10.24
- KMDA $6.78
- Resistance Level
- SD $12.64
- KMDA $7.09
- Average True Range (ATR)
- SD 0.32
- KMDA 0.16
- MACD
- SD 0.16
- KMDA 0.04
- Stochastic Oscillator
- SD 78.81
- KMDA 98.48
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.